COMMUNIQUÉS West-GlobeNewswire

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
16/09/2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
16/09/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: [...]
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
16/09/2026
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and [...]
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
16/09/2026
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ® Combining ART27.13 with semaglutide [...]
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
16/09/2026
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice [...]
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
16/09/2026
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced [...]
ESA Letter in Utah: RealESALetter.com Gains Recognition Among Utah Residents
16/09/2026
SALT LAKE CITY, UT, Sept. 16, 2026 (GLOBE NEWSWIRE) -- RealESALetter.com connects Utah residents with licensed mental health professionals for individualized emotional support animal (ESA) evaluations and documentation [...]
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
16/09/2026
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and [...]
MESSAGE DU CEO DE TME PHARMA
16/09/2026
MESSAGE DU CEO DE TME PHARMA Berlin, Allemagne, le 16 septembre 2026, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le développement de [...]
TME PHARMA CEO MESSAGE
16/09/2026
TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for [...]
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
16/09/2026
September 16, 2026 News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“ [...]
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
16/09/2026
Late Breaking Oral Presentation at 26th EURETINA Congress, 1-4 October 2026, Vienna PARIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing [...]
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
16/09/2026
New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® [...]
UpFront Diagnostics obtient le marquage CE pour LVOne, premier test sanguin rapide au monde destiné au diagnostic de l’AVC
16/09/2026
LVOne est le seul kit de diagnostic sanguin destiné au diagnostic de l’AVC à avoir obtenu le marquage CE CAMBRIDGE, Royaume-Uni, 16 sept. 2026 (GLOBE NEWSWIRE) -- UpFront Diagnostics annonce l’obtention du marquage CE [...]
UpFront Diagnostics Announces CE Mark Approval for LVOne — the World's First Rapid Blood Test to Diagnose Stroke
16/09/2026
LVOne is the only blood-based diagnostics kit for stroke diagnosis to be CE certified CAMBRIDGE, United Kingdom, Sept. 16, 2026 (GLOBE NEWSWIRE) -- UpFront Diagnostics has announced CE mark approval for LVOne—the world' [...]
EIB and Angelini Ventures’ Partnership Reaches €48.5 Million in Investments
16/09/2026
Rome, 16 September 2026 New €17 million investment into MMI, a microsurgery robotics company, marks the third investment completed under the €150 million partnership in less than 12 months, following ADCytherix and [...]
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events
16/09/2026
Oxford, UK, September 16, 2026 – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that members of its senior leadership team will participate in a [...]
Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
16/09/2026
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17 [...]
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
16/09/2026
Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing SYDNEY [...]

Pages